Cannabinoid Patch

1 . A composition capable of use in a buccal patch, a dermal patch, or a sublingual patch, tablet, capsule, pill, or strip, wherein the composition comprises one or more of:

(a) An acrylic adhesive with non-functionality and an adhesive with only OH-functionality, further comprising one of more of enhancers selected from azone, oleic acid, and dimethylsulfoxide (DMSO);

(b) A polyisobutylene (PIB adhesive) with tackifiers that improve adhesion to skin using acrylic pressure sensitive adhesive mixed in at 1-50%, optionally with a cycloaliphatic hydrocarbon resin;

(c) PIB adhesive with enhancers: at 3% of azone or oleic acid double the transdermal delivery from PIB. The disclosure provides a graph showing transdermal flux;

(d) Hemp oil with CBD of concentration 80-95% containing at least one terpene;

(e) A semisolid hydrogel that is saturated with cannabidiol (CBD) and tetrahydroxannabinol (THC);

(f) A semisolid hydrogel comprising an oil that consists essentially of CBD and THC (80-95%, wt/vol), in combination with ethanol/water (80/20, vol/vol), optionally with one or more enhancers selected from azone, oleic acid, and limonene;

(g) A semisolid hydrogel saturated with CBD and THC oils (80-95%, wt/vol), wherein the oil is mixed with EtOH/water (80/20, vol/vol), optionally with one or more enhancers selected from azone, oleic acid, and limonene; or

(h) A THC oil of THC (80-95%) mixed with 1-20% EtOH/water or with 1-10% EtOH/water (80/20, vol/vol) wherein including greater than 10% of ethanol is capable of lowering flux of THC delivery as determinable with a reservoir patch.

2 . A buccal patch comprising a composition of claim 1 .

3 . A dermal patch comprising a composition of claim 1 .

4 . A sublingual sublingual patch, tablet, capsule, pill, or strip, comprising a composition of claim 1 .

5 . A method for applying the buccal patch of claim 2 to the buccal mucosa of a human subject, and allowing a cannabinoid to transit from the patch into an oral mucosa of the human subject.

6 . A method for applying the dermal patch of claim 3 to skin of a human subject, and allowing a cannabinoid to transit from the buccal patch into the skin of the human subject.

7 . A method for applying the sublingual patch, tablet, capsule, pill, or strip of claim 4 , to the tongue of a human subject, and allowing a cannabinoid to transit from the sublingual patch, tablet, capsule, pill, or strip, into an oral mucosa of a the human subject.

8 . A method for manufacturing the patch of claim 1 , comprising the steps of combining THC, a film, an adhesive, and a backing, to generate an uncut patch, further comprising the uncut patch to produce a cut patch that is capable of applying to human skin or of applying to human buccal pouch.

9 . A method for delivering cannabidiol (CBD) to human skin, wherein the method comprises the step of contacting a dermal patch with the human skin, and wherein the contacting is for at least one hour, and wherein the delivering results in passage of CBD through the skin,

wherein the method uses a dermal patch that comprises polyisobutylene (PIB) and a cannabis oil that contains about 15% cannabidiol (CBD) oil, and wherein the delivering is measurable by a system that comprises human cadaver skin and a Franz diffusion cell, wherein said method is capable of delivering one or both of:

(i) A cumulative flux of CBD of at least about 20 micrograms CBD per cm 2 of skin over a period often hours, and

(ii) A cumulative flux of CBD of at least about 40 micrograms CBD per cm 2 of skin over a period of twenty hours.

10 . A method for delivering tetrahydrocannabinol (THC) to human skin, wherein the method comprises the step of contacting a dermal reservoir patch with the human skin, and wherein the contacting is for at least one hour, and wherein the delivering results in passage of THC through the skin,

the method resulting in cumulative flux of THC from a saturated ethanol/water solution with 25% THC oil, and wherein one or both of:

(i) The ratio of ethanol/water is about 70/30 and the flux is at least about 40 micrograms THC per cm 2 , and

(ii) The ratio of ethanol/water is about 60/40 and flux is at least about 50 micrograms TI-C per cm 2 .

11 . A sublingual tablet of about 250 mg, wherein the sublingual tablet comprises CBD (20 mg) and melatonin (3 mg), and wherein the sublingual tablet has a friability of about 0.3%, a hardness of about 3 kg/cm2, and a disintegration of about 45 seconds.